Amgen submitted a new analysis to the FDA supporting its position to keep Tavneos on the market. The latest package is intended to address a continuing regulatory dispute around the controversial rare disease drug. The filing adds another step to a process that has already forced Amgen into repeated rounds of data review and argumentation. The company’s next moves will likely depend on what FDA regulators consider sufficient for benefit-risk under the labeling at issue.